The U.S. Food and Drug Administration (FDA) has approved Saol Therapeutics’ LYVISPAH (baclofen) oral granules for the treatment of spasticity, flexor spasms, concomitant pain, and muscular rigidity resulting from multiple sclerosis (MS). LYVISPAH, as opposed to previous formulations of baclofen, is particularly important because it is now approved for administration with or without water, with soft foods, and enteral feeding tubes, while also having the potential to affect patients with spinal cord injuries or diseases. The spasticity that patients with MS experience may often lead to the development of swallowing difficulties, with the rate of spasticity as high as 67% among the nearly million patients with MS. LYVISPAH will be fully commercially launched following this approval, per Saol Therapeutics’ plans. As a biopharmaceutical company with global operations, Saol is committed to the commercial and clinical development of therapeutics focused on disorders of the CNS, providing therapeutic options for patients who have unmet needs related to these disorders.  

Read more here